Teladoc Health (NYSE:TDOC – Get Rating) had its price objective reduced by equities research analysts at Oppenheimer from $130.00 to $65.00 in a report released on Thursday, The Fly reports. Oppenheimer’s price objective suggests a potential upside of 16.09% from the company’s current price.
Several other analysts also recently issued reports on the company. SVB Leerink decreased their target price on Teladoc Health from $193.00 to $161.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 23rd. Citigroup cut Teladoc Health from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $115.00 to $43.00 in a report on Thursday. Craig Hallum dropped their target price on Teladoc Health from $82.00 to $67.00 and set a “hold” rating for the company in a report on Wednesday, February 23rd. Canaccord Genuity Group dropped their target price on Teladoc Health from $160.00 to $112.00 in a report on Wednesday, February 23rd. Finally, Royal Bank of Canada dropped their price objective on Teladoc Health from $215.00 to $120.00 and set an “outperform” rating for the company in a report on Tuesday, April 12th. One equities research analyst has rated the stock with a sell rating, sixteen have given a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, Teladoc Health currently has a consensus rating of “Hold” and an average price target of $100.21.
NYSE TDOC opened at $55.99 on Thursday. Teladoc Health has a 12 month low of $50.08 and a 12 month high of $189.65. The stock has a market cap of $9.02 billion, a P/E ratio of -20.21 and a beta of 0.43. The stock’s fifty day moving average price is $65.99 and its 200-day moving average price is $90.30. The company has a current ratio of 3.70, a quick ratio of 3.48 and a debt-to-equity ratio of 0.08.
In other news, insider Adam C. Vandervoort sold 3,513 shares of the firm’s stock in a transaction on Thursday, March 3rd. The stock was sold at an average price of $70.24, for a total transaction of $246,753.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Stephany Verstraete sold 2,858 shares of the firm’s stock in a transaction on Thursday, March 3rd. The stock was sold at an average price of $70.24, for a total value of $200,745.92. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,842 shares of company stock valued at $1,042,502. Insiders own 6.47% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Liberty Wealth Management LLC raised its stake in shares of Teladoc Health by 450.0% in the third quarter. Liberty Wealth Management LLC now owns 209 shares of the health services provider’s stock valued at $28,000 after acquiring an additional 171 shares in the last quarter. Hudock Inc. raised its stake in shares of Teladoc Health by 111.7% in the third quarter. Hudock Inc. now owns 290 shares of the health services provider’s stock valued at $36,000 after acquiring an additional 153 shares in the last quarter. Future Financial Wealth Managment LLC acquired a new stake in shares of Teladoc Health in the fourth quarter valued at $29,000. TCTC Holdings LLC acquired a new stake in shares of Teladoc Health in the third quarter valued at $41,000. Finally, CarsonAllaria Wealth Management Ltd. acquired a new stake in shares of Teladoc Health in the fourth quarter valued at $30,000. Institutional investors and hedge funds own 86.68% of the company’s stock.
About Teladoc Health (Get Rating)
Teladoc Health, Inc provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions.
- Get a free copy of the StockNews.com research report on Teladoc Health (TDOC)
- Facebook (NASDAQ: FB) Soars And Wall Street Delights
- Automatic Data Processing Is Ready To Scale New Heights
- Carl Icahn Buys More Xerox
- Xerox Holdings Stock is a Value Play
- The Kraft Heinz Turnaround Story Gains Momentum
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.